Provided by Tiger Trade Technology Pte. Ltd.

Arcutis Biotherapeutics Inc.

23.89
+0.50502.16%
Post-market: 23.890.00000.00%16:10 EDT
Volume:2.04M
Turnover:48.89M
Market Cap:2.99B
PE:110.88
High:24.18
Open:23.63
Low:23.55
Close:23.38
52wk High:31.77
52wk Low:16.57
Shares:125.07M
Float Shares:111.18M
Volume Ratio:0.90
T/O Rate:1.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2154
EPS(LYR):-0.1269
ROE:15.86%
ROA:5.09%
PB:13.54
PE(LYR):-188.28

Loading ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 03

Arcutis Biotherapeutics to present at Goldman Sachs Global Healthcare Conference

Reuters
·
May 27

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Abivax SA Sponsored ADR (ABVX) and Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
May 26

Arcutis Earnings Call Signals Momentum Amid Headwinds

TIPRANKS
·
May 11

Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4

Reuters
·
May 09

Arcutis grants 269,000 RSUs, 70,000 stock options to new hires under inducement plan

Reuters
·
May 09

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 09

Arcutis Biotherapeutics price target lowered to $34 from $35 at Morgan Stanley

TIPRANKS
·
May 08

Stock Track | Arcutis Biotherapeutics Plunges 5.23% in Pre-market Following Q1 Earnings Miss and Insider Selling

Stock Track
·
May 07

Arcutis Biotherapeutics Price Target Maintained With a $36.00/Share by Needham

Dow Jones
·
May 07

Analysts Conflicted on These Healthcare Names: Quanterix (QTRX) and Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
May 07

Stock Track | Arcutis Biotherapeutics Plunges 6.91% After Q1 Earnings Miss Estimates

Stock Track
·
May 07

Arcutis Chief Legal Officer Masaru Matsuda disposes 8,256 shares worth $192,893

Reuters
·
May 07

Arcutis Biotherapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Arcutis Q1 FY26 net loss narrows to USD 11.3 million; revenue rises 65% to USD 105.4 million

Reuters
·
May 07

Arcutis Biotherapeutics Q1 EPS USD -0.09

THOMSON REUTERS
·
May 07

Arcutis Biotherapeutics Q1 Product Revenue USD 105.398 Million

THOMSON REUTERS
·
May 07

Arcutis Biotherapeutics Inc - Sees FY2026 Net Product Revenue $480 Mln-$495 Mln

THOMSON REUTERS
·
May 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 06

Arcutis director Howard Welgus sells 7,144 shares for $164,203.54

Reuters
·
May 06